Cross-source identity
National Provider Identifier 1093880957 as it appears in every federal dataset Fonteum holds. Each row is a distinct public source; the chip carries the source and the snapshot date behind that field — the record-level form of the source-provenanced graph.
| Federal source | Key | What it provides | Provenance |
|---|---|---|---|
| CMS Open Payments |
| NPI 1093880957 |
| 229 industry-payment records, 2024 |
| Source:CMS Open PaymentsSnapshot PY2024 |
| CMS Medicare Part D | NPI 1093880957 | 212 drugs prescribed, 2024 | Source:CMS Part DSnapshot DY2024 |
| Fonteum entity graph | entity f5500c6a… | Canonical resolved node · 4 identifier(s) · 14 edge(s) | Source:Entity graphSnapshot 2026-06-11 |
Industry payments
Payments and transfers of value this clinician received from drug and device manufacturers, disclosed under the Physician Payments Sunshine Act. A payment is a disclosure, not a judgment.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $5,112 | 227 |
| Education | $145 | 2 |
| Manufacturer | Amount | Records |
|---|---|---|
| Iti, Inc. (D/B/A Intra-Cellular Therapies, Inc.) | $581 | 22 |
| Astrazeneca Pharmaceuticals Lp | $458 | 15 |
| Lilly Usa, Llc | $316 |
Prescribing
Prescriptions written under Medicare Part D, aggregated by drug across the program. Totals reflect claims paid, not patients treated.
| Drug | Claims | Drug cost |
|---|---|---|
| Januvia(Sitagliptin Phosphate) | 249 | $297,101 |
| Jardiance(Empagliflozin) | 120 | $179,258 |
| Eliquis(Apixaban) | 119 | $138,382 |
| Linzess(Linaclotide) | 110 | $110,389 |
| Ozempic(Semaglutide) | 69 | $108,403 |
Beneficiary counts below 11 are suppressed by CMS — the total shown is a lower bound.
Quality
CMS Quality Payment Program Merit-based Incentive Payment System (MIPS) final score, where this clinician participated. Absence of a score is not a quality signal — many clinicians report through a group or are exempt.
Enrollment & sanctions
Screening aid — re-confirm any match against the issuing list before acting. A clean result means no record was found in the federal OIG LEIE or the state Medicaid lists Fonteum currently holds (NY, OH, GA), not a guarantee that none exists elsewhere. Not a legal or credentialing certification.
Ownership & affiliations
One-hop relationships in the resolved entity graph — chain membership, ownership, and operation edges, each backed by a federal source row. Most individual clinicians carry none; edges populate for owners and organizations as the Lane D backfill runs.
| Relationship | Entity | Source |
|---|---|---|
| ← pays | Janssen Pharmaceuticals, Inc (NJ) | cms_open_payments |
| ← pays | Bayer Healthcare Pharmaceuticals Inc. (NJ) | cms_open_payments |
| ← pays | Novartis Pharmaceuticals Corporation (NJ) | cms_open_payments |
| ← pays | Novo Nordisk Inc (NJ) | cms_open_payments |
| ← pays | E.R. Squibb & Sons, L.L.C. (NJ) | cms_open_payments |
| ← pays | Astrazeneca Pharmaceuticals Lp (DE) | cms_open_payments |
| ← pays | Abbvie Inc. (IL) | cms_open_payments |
| ← pays | Eisai Inc. (NJ) | cms_open_payments |
| ← pays | Amgen Inc. (CA) | cms_open_payments |
| ← pays | Opko Pharmaceuticals, Llc (FL) | cms_open_payments |
| ← pays | Kowa Pharmaceuticals America, Inc. (AL) | cms_open_payments |
| ← pays | Exact Sciences Corporation (WI) | cms_open_payments |
| ← pays | Glaxosmithkline, Llc. (PA) | cms_open_payments |
| ← pays | Insulet Corporation (MA) | cms_open_payments |
| 10 |
| Abbvie Inc. | $299 | 16 |
| Novo Nordisk Inc | $291 | 14 |